Immunosuppressive tumor-infltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma

Neuro-Oncology

Volumn 19, Issue 6, 2017, Pages 796-807

  Antonios, Joseph P ^a   Soto, Horacio ^a   Everson, Richard G ^a   Moughon, Diana ^a   Orpilla, Joey R ^a   Shin, Namjo P ^a   Sedighim, Shaina ^a   Treger, Janet ^a   Odesa, Sylvia ^a   Tucker, Alexander ^a   Yong, William H ^a   Li, Gang ^a   Cloughesy, Timothy F ^a,b,c   Liau, Linda M ^a,b,c   Prins, Robert M ^a,b,c  

^a Department of Neurosurgery ^*  (United States)

^b Brain Research Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; Checkpoint inhibitors; CSF 1R; Dendritic cell vaccine; Glioblastoma; immunotherapy; PD 1

Indexed keywords

CHEMOTACTIC FACTOR; PROGRAMMED DEATH 1 RECEPTOR; CANCER VACCINE; CD274 PROTEIN, HUMAN; COLONY STIMULATING FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG SCREENING; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; CANCER VACCINES; FEMALE; GLIOBLASTOMA; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MYELOID CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018060012     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now287     Document Type: Article

References (47)

1. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.
2. Prins RM, Wang X, Soto H, et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded den-dritic cell vaccination in malignant glioma patients. J Immunother. 2013;36(2):152-157.
3. Heimberger AB, Hussain SF, Aldape K, et al. Tumor-specifc peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol. 2006;24(18):107s.
4. Kanaly CW, Ding D, Heimberger AB, et al. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am. 2010;21(1):95-109.
5. Prins RM, Soto H, Konkankit V, et al. Gene expression profle correlates with T-cell infltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615.
6. Antonios J P, Soto H, Everson RG, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10): pii: e87059.
7. Taube JM, Anders RA, Young GD, et al. Colocalization of infammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra137.
8. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.
9. Zeng J, See A P, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-349.
10. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic effcacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290-5301.
11. Bloch O, Crane CA, Kaur R, et al. Gliomas promote immunosuppres-sion through induction of B7-H1 expression in tumor-associated mac-rophages. Clin Cancer Res. 2013;19(12):3165-3175.
12. Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501-1509.
13. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-88.
14. Schultheis AM, Scheel AH, Ozretic L, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51(3):421-426.
15. Qu QX, Huang Q, Shen Y, et al. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer. Tumour Biol. 2016;37(4):5031-5037.
16. Krempski J, Karyampudi L, Behrens MD, et al. Tumor-infltrating pro-grammed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011;186(12):6905-6913.
17. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-5074.
18. Soares KC, Rucki AA, Wu AA, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infltration into pancreatic tumors. J Immunother. 2015;38(1):1-11.
19. Prall F, Huhns M. PD-L1 expression in tumour buds of colorectal carci-noma. Histopathology. 2016;69(1):158-160.
20. Mathios D, Ruzevick J, Jackson CM, et al. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol. 2015;121(2):251-259.
21. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 pro-motes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-740.
22. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605-612.
23. Escamilla J, Schokrpur S, Liu C, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015;75(6):950-962.
24. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infltrating myeloid cells and improves the effcacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9):2782-2794.
25. Stafford JH, Hirai T, Deng L, et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol. 2016;18(6):797-806.
26. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272.
27. Movahedi K, Guilliams M, Van den Bossche J, et al. Identifcation of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233-4244.
28. Gabrilovich D, Nefedova Y. ROR1C regulates differentiation of myeloid-derived suppressor cells. Cancer Cell. 2015;28(2):147-149.
29. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6(4):409-421.
30. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
31. Ben-Baruch A. Infammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16(1):38-52.
32. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mono-nuclear phagocytes. Trends Immunol. 2002;23(11):549-555.
33. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23-35.
34. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated mac-rophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254-265.
35. Nishie A, Ono M, Shono T, et al. Macrophage infltration and heme oxy-genase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999;5(5):1107-1113.
36. Rossi ML, Jones NR, Candy E, et al. The mononuclear cell infltrate compared with survival in high-grade astrocytomas. Acta Neuropathol. 1989;78(2):189-193.
37. Antonios J P, Soto H, Everson R, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10). pii: e87059.
38. Malkov VA, Serikawa KA, Balantac N, et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. BMC Res Notes. 2009;2:80.
39. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantifcation of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009;119(6):1714-1726.
40. Peper JK, Schuster H, Loffer MW, et al. An impedance-based cytotox-icity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods. 2014;405:192-198.
41. Everson RG, Antonios JP, Lisiero DN, et al. Effcacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol. 2016;18(3):368-378.
42. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783-784.
43. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272.
44. Quail DF, Bowman RL, Akkari L, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352(6288):aad3018.
45. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030.
46. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004-2012.
47. Garon EB, Rizvi NA, Hui R, et al.; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.